Plain-English translation of NCT06903559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a newer oral medication for treating anemia in people on kidney dialysis, might offer benefits beyond just raising blood counts. Researchers want to see if this medication can also help protect heart health and improve overall nutrition and inflammation — problems that commonly affect dialysis patients. The medication works by stimulating your body's natural production of red blood cells.
People on kidney dialysis almost always develop anemia (low red blood cell counts), which makes them tired and increases their risk of heart disease. Current treatments work, but researchers want to know if this newer medication might offer extra benefits for heart health and reduce the inflammation and nutritional problems that dialysis patients often face.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the new medication three times per week by mouth, or continue your current anemia treatment, for 6 months. Both groups will receive standard care for other health conditions. Throughout the study, your doctors will monitor your blood counts, heart health, nutrition, and inflammation levels to see if the new medication helps more than current treatments.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Egypt
Phase
Safety & dosing / Early efficacy
Sponsor
Mansoura University
Enrollment target
~46 participants
Started
April 2025
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ibrahim M Galalah, MSC
Mansoura University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.